Abstract
A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have